News
-
-
COMMUNIQUÉ DE PRESSE
DEBRA Research Collaborates with Queen Mary University of London to Advance Drug Development for Epidermolysis bullosa
DEBRA Research collaborates with Queen Mary University of London to advance drug development for Epidermolysis bullosa. Partnership aims to accelerate research and innovation in tackling this rare skin condition -
-
-
COMMUNIQUÉ DE PRESSE
DEBRA Research and Dermaliq Enter into a Strategic Collaboration to Advance Cutaneous Drug Delivery for Epidermolysis Bullosa
DEBRA Research and Dermaliq partner to advance cutaneous drug delivery for Epidermolysis Bullosa, focusing on innovative topical treatments and therapies using hyliQ technology -
-
-
COMMUNIQUÉ DE PRESSE
DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa
DEBRA Research announces impact investment into Nova Anchora to advance protein therapy for Epidermolysis Bullosa. Global investors support development of NvA-011 for rare skin disorder treatment -
-